Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibodies, isotypes and complement in allograft rejection.
Böhmig GA, Bartel G, Wahrmann M. Böhmig GA, et al. Among authors: wahrmann m. Curr Opin Organ Transplant. 2008 Aug;13(4):411-8. doi: 10.1097/MOT.0b013e3283028312. Curr Opin Organ Transplant. 2008. PMID: 18685338 Review.
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S, Böhmig GA. Mühlbacher J, et al. Among authors: wahrmann m. Transplantation. 2017 Oct;101(10):2410-2418. doi: 10.1097/TP.0000000000001804. Transplantation. 2017. PMID: 28926521 Free PMC article. Clinical Trial.
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F, Dürr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Mühlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Böhmig GA. Eskandary F, et al. Among authors: wahrmann m. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6. Trials. 2019. PMID: 30635033 Free PMC article.
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena.
Borski A, Eskandary F, Haindl S, Doberer K, Mühlbacher J, Mayer KA, Budde K, Halloran PF, Chong E, Jilma B, Böhmig GA, Wahrmann M. Borski A, et al. Among authors: wahrmann m. Transplantation. 2023 Feb 1;107(2):495-503. doi: 10.1097/TP.0000000000004285. Epub 2023 Jan 26. Transplantation. 2023. PMID: 35969004 Clinical Trial.
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Böhmig GA. Eskandary F, et al. Among authors: wahrmann m. Am J Transplant. 2018 Apr;18(4):916-926. doi: 10.1111/ajt.14528. Epub 2017 Oct 31. Am J Transplant. 2018. PMID: 28980446 Free article. Clinical Trial.
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, Reeve J, Borski A, Kozakowski N, Reindl-Schwaighofer R, Waiser J, Lachmann N, Schranz S, Firbas C, Mühlbacher J, Gelbenegger G, Perkmann T, Wahrmann M, Kainz A, Ristl R, Halleck F, Bond G, Chong E, Jilma B, Böhmig GA. Doberer K, et al. Among authors: wahrmann m. J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18. J Am Soc Nephrol. 2021. PMID: 33443079 Free PMC article. Clinical Trial.
74 results